Lantheus Holdings, Inc. (LNTH) stock
LNTHNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3012% above fair value
$101.80+0.08 (+0.08%)
Close on Nov 17, 2026Market cap $6.64BP/E 24.6Yield –
Lantheus operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Lantheus's operating income for the twelve months ending Jun 30, 2026 was $302.34M, down 30.9% year over year. For fiscal 2025 it was $310.83M, down 32.0% from the year before. Over ten years it grew 22.0% a year on average. The highest annual figure on record is $456.98M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $310.83M | -32.0% |
| FY2024 | Dec 31, 2024 | $456.98M | +25.3% |
| FY2023 | Dec 31, 2023 | $364.64M | +907.4% |
| FY2022 | Dec 31, 2022 | $36.20M | – |
| FY2021 | Dec 31, 2021 | -$60.83M | – |
| FY2020 | Dec 31, 2020 | -$4.20M | -108.1% |
| FY2019 | Dec 31, 2019 | $51.66M | -19.9% |
| FY2018 | Dec 31, 2018 | $64.49M | +24.4% |
| FY2017 | Dec 31, 2017 | $51.85M | -8.4% |
| FY2016 | Dec 31, 2016 | $56.59M | +33.1% |
| FY2015 | Dec 31, 2015 | $42.53M | +7.9% |
| FY2014 | Dec 31, 2014 | $39.42M | – |
| FY2013 | Dec 31, 2013 | -$18.89M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $100.22M | +13.9% |
| Q1 FY2026 | Mar 31, 2026 | $81.33M | -20.3% |
| Q4 FY2025 | Dec 31, 2025 | $77.18M | -32.2% |
| Q3 FY2025 | Sep 30, 2025 | $43.62M | -67.4% |
| Q2 FY2025 | Jun 30, 2025 | $87.97M | -14.4% |
| Q1 FY2025 | Mar 31, 2025 | $102.07M | -4.3% |
| Q4 FY2024 | Dec 31, 2024 | $113.87M | -17.2% |
| Q3 FY2024 | Sep 30, 2024 | $133.74M | +19.0% |
| Q2 FY2024 | Jun 30, 2024 | $102.73M | -17.2% |
| Q1 FY2024 | Mar 31, 2024 | $106.64M | – |
| Q4 FY2023 | Dec 31, 2023 | $137.49M | – |
| Q3 FY2023 | Sep 30, 2023 | $112.36M | +31.0% |
| Q2 FY2023 | Jun 30, 2023 | $124.14M | +96.4% |
| Q1 FY2023 | Mar 31, 2023 | -$9.34M | -115.9% |
| Q4 FY2022 | Dec 31, 2022 | -$171.68M | – |
| Q3 FY2022 | Sep 30, 2022 | $85.74M | – |
| Q2 FY2022 | Jun 30, 2022 | $63.20M | – |
| Q1 FY2022 | Mar 31, 2022 | $58.93M | +277.2% |
| Q4 FY2021 | Dec 31, 2021 | -$35.34M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.33M | – |
| Q2 FY2021 | Jun 30, 2021 | -$26.78M | – |
| Q1 FY2021 | Mar 31, 2021 | $15.62M | +119.3% |
| Q4 FY2020 | Dec 31, 2020 | -$528.00K | -104.2% |
| Q3 FY2020 | Sep 30, 2020 | -$5.25M | -161.6% |
| Q2 FY2020 | Jun 30, 2020 | -$5.55M | -138.1% |
| Q1 FY2020 | Mar 31, 2020 | $7.13M | -55.9% |
| Q4 FY2019 | Dec 31, 2019 | $12.44M | -26.6% |
| Q3 FY2019 | Sep 30, 2019 | $8.52M | -48.3% |
| Q2 FY2019 | Jun 30, 2019 | $14.54M | -8.7% |
| Q1 FY2019 | Mar 31, 2019 | $16.17M | +6.8% |
| Q4 FY2018 | Dec 31, 2018 | $16.94M | +84.0% |
| Q3 FY2018 | Sep 30, 2018 | $16.48M | +28.5% |
| Q2 FY2018 | Jun 30, 2018 | $15.93M | -11.0% |
| Q1 FY2018 | Mar 31, 2018 | $15.14M | +26.9% |
| Q4 FY2017 | Dec 31, 2017 | $9.21M | -24.2% |
| Q3 FY2017 | Sep 30, 2017 | $12.82M | +1.8% |
| Q2 FY2017 | Jun 30, 2017 | $17.90M | – |
| Q1 FY2017 | Mar 31, 2017 | $11.93M | – |
| Q4 FY2016 | Dec 31, 2016 | $12.14M | – |
| Q3 FY2016 | Sep 30, 2016 | $12.60M | – |
See a number that looks wrong?